Table 1.

Approved drugs with anti-COVID-19 viral activity.

Drugs	Conventional Use	Dosage	Administration Routes
Interferon-α	Hepatitis, pneumonia	5 million U (2 mL of sterile water for injection) each time, 2 times/day	Vapor inhalation, intramuscular injection
Lopinavir–ritonavir	Human immunodeficiency virus	400 mg/100 mg each time, 2 times/day	Oral
Ribavirin	Viral infection	500 mg each time, 2–3 times/day in combination with IFN-α or lopinavir/ritonavir	Intravenous infusion
Chloroquine phosphate	Malaria	500 mg (300 mg for chloroquine) each time, 2 times/day	Oral
Arbidol	Infection of the upper respiratory tract	200 mg each time, 3 times/day	Oral
Favipiravir	Flu virus	On day 1, 800 mg each time; on days 2–5, 300 mg each time, 2 times/day	Oral
Remdesivir	Respiratory virus, hepatitis C	On day 1, 200 mg/day; on days 2–9, 100 mg/day	Intravenous infusion